To date, the project participants have planned the following actions:


Name of the planned action

Term for control over implementation


Obtaining of permission from the Ministry of Health of the Russian Federation to conduct the 2nd phase of CT

June 2019 - September 2019


Conducting of CT of the 2nd phase in Russia

September 2019 - September 2021


Involvement of a strategic investor in the project

September 2020 - September 2021

We expect that the first positive results for patients received during the 2nd phase of CT in Russia will be of interest in regard to attracting partners in the USA. For this end, we plan to register a legal entity in the USA and transfer assets to it on a territorial basis, leaving PharmaDiall LLC the right to promote the drug in the CIS (Eurasian patent and patent of Ukraine). Possible partners in the USA are first of all representatives of Big Pharma: Bayer and Boehringer Ingelheim as well as. With their help, we expect to conduct the necessary clinical trials in the USA.